Second, our study suggests that the slightly increased pCR rate of combined neoadjuvant immunochemotherapy in patients with stage IIIA NSCLC with nodal involvement in the CheckMate 816 trial (pCR 22%) compared with the sequential approach in the SAKK 16/14 trial (pCR 18%) is not due to the influence of CT on the PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.